Tags : SentreHEART

Atricure to Acquire SentreHEART for Expansion of Therapies to Treat

Vartika Singh August 12, 2019

Shots: Atricure acquires SentreHEART in all stock and cash transaction. Atricure to pay upfront as ~$40M in cash and AtriCure common stock, ~$140M milestones based on aMAZE IDE clinical trial […]readmore

Tags : SentreHEART

Atricure to Acquire SentreHEART for Expansion of Therapies to Treat

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : SentreHEART

Atricure to Acquire SentreHEART for Expansion of Therapies to Treat

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company